AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 11 min read$ANIP

CAREY STEPHEN P. sold $207K of ANIP

CAREY STEPHEN P. (SVP & CFO) sold 2,850 shares of ANI PHARMACEUTICALS INC (ANIP) at $72.80 ($0.21M total) on 2026-08-31 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CAREY STEPHEN P.
Published Sep 1, 2026, 10:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 10:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ANIP
Bearish
medium confidence
Mentioned
$ANIP
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANIPBearishLow
01

Why it matters

The CFO's sale reduces his ownership and may be interpreted as a negative signal, though the amount is modest.

02

Market read

Primary insider sale filing; modest impact but worth noting for short‑term traders.

03

What to watch

Potential tax planning or portfolio rebalancing could be driving the transaction rather than company outlook.

Relevance 3/10Novelty 4/10Timing: post‑market 2026‑08‑31

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$ANIPBearishMedium confidence
Context

CFO Stephen Carey sold 2,850 shares for $207,480 via a 10b5‑1 plan, reducing his stake to 171,843 shares.

Expected impact

Modest downward pressure; price may dip 1‑2% in the next trading session.

Evidence & confidence

The sale amount is modest ($207k) but involves the CFO, suggesting a possible negative signal to the market.

Market effects

Sector

Minimal; the sale does not affect the broader pharmaceutical sector.

Regional

Limited to U.S. investors tracking ANI Pharmaceuticals.

Global

Low; no global macro implications.

Counterpoint

What could challenge this read

The sale may be routine under a pre‑arranged 10b5‑1 plan and not indicative of insider sentiment.

Key entities

  • Company
    ANI Pharmaceuticals Inc

    U.S. pharmaceutical company (ticker ANIP).

  • Executive
    Stephen P. Carey

    Senior Vice President & Chief Financial Officer of ANI Pharmaceuticals.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ANIP insider trading history →

Related articles

OCT 12
$ANIPHighAI 8/10

ANI Pharmaceuticals Report Two-Year Vision Improvements In Phase 4 Eye Disease Study

ANI Pharmaceuticals (ANIP) reported positive results from its Phase 4 SYNCHRONICITY trial for the Fluocinolone Acetonide Intravitreal Implant in treating chronic non-infectious uveitis affecting the posterior segment of the eye. The trial met primary endpoints at six months and maintained improvements through 24 months. The implant is approved in the U.S. for chronic NIU-PS and diabetic macular edema. ANIP's stock closed at $73.89, up 2.65%.

rttnews.com2 min
OCT 12
$ANIPMedAI 8/10

ANI reports positive results from uveitis implant trial

ANI Pharmaceuticals (NASDAQ:ANIP) reported positive Phase 4 trial results for its fluocinolone acetonide implant in treating chronic non-infectious uveitis. The trial met primary endpoints, showing sustained improvements in visual acuity and central subfield thickness over 24 months. Adverse events included ocular hypertension and cataract. The implant was previously FDA-approved for diabetic macular edema and uveitis treatment.

investing.com2 min
OCT 12
$ANIPMedAI 8/10

After one implant, 79.6% of treated eyes had no inflammation return for two years

ANI Pharmaceuticals reported 6-month and 24-month data from its SYNCHRONICITY trial of fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis. The trial met co-primary endpoints with statistical significance, showing improvements in visual acuity and central subfield thickness. At 24 months, 79.6% of treated eyes had no inflammation recurrence. Adverse events were consistent with prior trials.

stocktitan.net2 min
SEP 30
$ANIPMedAI 8/10

ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting

ANI Pharmaceuticals (ANIP) will present data from its Phase 4 SYNCHRONICITY trial and post-hoc analyses from the NEW DAY trial at the American Academy of Ophthalmology 2026 Meeting. The trials involve Fluocinolone Acetonide Intravitreal Implant for chronic non-infectious uveitis and diabetic macular edema. The company also plans an encore presentation at the Hawaiian Eye & Retina 2027 Meeting.

globenewswire.com1 min